- October 2015
Milena Sant on the latest results from the EUROCARE study.
- September 2015
The science behind the IARC code that could reduce cancer in Europe.
- July/August 2015
Thomas Helleday on an exciting new class of drug, MTH1 inhibitors.
- June 2015
Lesley Seymour and Jan Bogaerts on the future of RECIST.
- May 2015
Paul Workman on strategies for overcoming resistance to new drugs.
- April 2015
Highlights from the TAT Congress in Paris.
- March 2015
Christopher Wild on the exposome, a measure of environmental exposure.
- February 2015
Mathematicians are developing a blood flow model for metastasis.
- January 2015
René Bernards on discovering effective drug combinations.
- December 2014
Research on the high rate of burnout among young oncologists.
- November 2014
Carl June on the efficacy of CAR-T cells in treating leukaemia.
EJC News Focus – November 2013
Highlights of European Cancer Congress
"Astonishing" results with immunotherapy in a range of hard to treat cancers were the highlight of the Congress (27 September – 1st October, 2013) for Martine Piccart (ESMO). For Vincenzo Valentini (ESTRO), it was the new perception that that local treatment with radiation therapy could have an impact on systemic disease. Graeme Poston (ESSO) picked out the training of young surgical oncologists, which may now last only 6,000 hours, compared with up to 40,000 hours for previous generations of surgeons. How can the profession ensure that they are safe?
In this month's EJC News Focus, Helen Saul meets the Presidents of various cancer societies, including Moshe Oren (EACR), Birgitte Grube (EONS) and Cornelis van de Velde (ECCO), and asks for their take-home messages from the European Cancer Congress.